Role of iron in inducing oxidative stress in thalassemia: Can it be prevented by inhibition of absorption and by antioxidants?

Annals of the New York Academy of Sciences

Volumn 1054, Issue , 2005, Pages 118-123

  Rachmilewitz, Eliezer A ^a   Weizer Stern, Orly ^b   Adamsky, Konstantin ^b   Amariglio, Ninette ^b   Rechavi, Gideon ^b   Breda, Laura ^c   Rivella, Stefano ^c   Cabantchik, Z Ioav ^d  

^a WOLFSON MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Antioxidant; Hepcidin; Iron overload; Oxidative stress; Thalassemia

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; FLUORESCENT DYE; HEPCIDIN; IRON; IRON CHELATING AGENT; REACTIVE OXYGEN METABOLITE; RNA;

CELL DAMAGE; CELL STRAIN HEPG2; CELL SURFACE; CONFERENCE PAPER; DOWN REGULATION; ERYTHROCYTE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION REGULATION; GENE THERAPY; HUMAN; IRON ABSORPTION; IRON BLOOD LEVEL; IRON OVERLOAD; LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; THALASSEMIA;

EID: 29744461403     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1345.014     Document Type: Conference Paper

References (35)

1. GU, X. & Y. ZENG. 2002. A review of the molecular diagnosis of thalassemia. Hematology 7: 203-209.
2. WEATHERALL, D.J., L. PRESSLEY, W.G. WOOD, et al. 1981. Molecular basis for mild forms of homozygous beta-thalassaemia. Lancet 1: 527-529.
3. HOFFBRAND, A.V. 2001. Diagnosing myocardial iron overload. Eur. Heart J. 22: 2140-2141.
4. KUSHNER, J.P., J.P. PORTER & N.F. OLIVIERI. 2001. Secondary iron overload. Hematology (Am. Soc. Hematol. Educ. Program): 47-61.
5. RACHMILEWITZ, E.A. & S. SCHRIER. 2001. The pathophysiology of β-thalassemia. In Disorders of Hemoglobin: Genetics, Pathophysiology and Clinical Management. M.H. Steinberg, B.G. Forget, D.R. Higgs, and R.L. Nagel, Eds.: 223-251. Cambridge University Press. Cambridge, MA.
6. HEBBEL, R.P. 1985. Auto-oxidation and a membrane associated "Fenton Reagent": a possible explanation for development of membrane lesions in sickle erythrocytes. Clin. Hematol. 14: 129-140.
7. HERSHKO, C., G. GRAHAMK, G.W. BATES, et al. 1978. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br. J. Haematol. 40: 255-263.
8. BREUER, W., C. HERSHKO & Z.I. CABANTCHIK. 2000. The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus. Sci. 23: 185-192.
9. GOSRIWATANA, I., O. LOREAL, S. LU, et al. 1999. Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin. Anal. Biochem. 273: 212-220.
10. ESPOSITO, B.P., W. BREUER, P. SIRANKAPRACHA, et al. 2003. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 102: 2670-2677.
11. HERSHKO, C.M., G.M. LINK, A.M. KONIJN & Z.I. CABANTCHIK. 2005. Iron chelation therapy. Curr. Hematol. 4: 110-116.
12. ESPOSITO, B.P., S. EPSZTEJN, W. BREUER, et al. 2002. A review of fluorescence methods for assessing labile iron in cells and biological fluids. Anal. Biochem. 304: 1-18.
13. KAKHLON, O. & Z.I. CABANTCHIK. 2002. The labile iron pool: characterization, measurement, and participation in cellular processes. Free Radic. Biol. Med. 33: 1037-1046.
14. EISENSTEIN, R.S. 2001. Iron regulatory proteins and the molecular control of mammalian iron metabolism. Annu. Rev. Nutr. 20: 627-662.
15. NAPIER, I., P. PONKA & D.R. RICHARDSON. 2005. Iron trafficking in the mitochondrion: novel pathways revealed by disease. Blood 105: 1867-1874.
16. ZHANG, A.S., A.D. SHEFTEL & P. PONKA. 2005. Intracellular kinetics of iron in reticulocytes: evidence for endosome involvement in iron targeting to mitochondria. Blood 105: 368-375.
17. PARK, C.H., E.V. VALORE, A.J. WARING, et al. 2001. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J. Biol. Chem. 276: 7806-7810.
18. KRAUSE, A., S. NEITZ, H.J. MAGERT, et al. 2000. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 480: 147-150.
19. GANZ, T. 2003. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102: 783-788.
20. NEMETH, E., M.S. TUTTLE, J. POWELSON, et al. 2004. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306: 2090-2093.
21. PIGEON, C., G. ILYIN, B. COURSELAUD, et al. 2001. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J. Biol. Chem. 276: 7811-7819.
22. NEMETH, E., E.V. VALORE, M. TERRITO, et al. 2003. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101: 2461-2463.
23. NICOLAS, G., L. VIATTE, M. BENNOUN, et al. 2002. Hepcidin, a new iron regulatory peptide. Blood Cells Mol. Dis. 29: 327-335.
24. RIVELLA, S., C. MAY, A. CHADBURN, et al. 2003. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. Blood 101: 2932-2939.
25. ADAMSKY, K., O. WEIZER, N. AMARIGLIO, et al. 2004. Decreased hepcidin mRNA expression in thalassemic mice. Br. J. Haematol. 124: 123-124.
26. WEIZER, O., K. ADAMSKY, N. AMARIGLIO, et al. mRNA expression of iron regulatory genes in thalassemia intermedia and thalassemia major mice models. Am. J. Hematol. In press.
27. WEIZER, O., K. ADAMSKY, N. AMARIGLIO, et al. Sera from thalassemia major patients down regulate hepcidin mRNA expression in hepatic cell line. In preparation.
28. LATUNDE-DADA, G.O., C.D. VULPE, G.J. ANDERSON, et al. 2004. Tissue-specific changes in iron metabolism genes in mice following phenylhydrazine-induced haemolysis. Biochim. Biophys. Acta 1690: 169-176.
29. SHALEV, O., T. REPKA, A. GOLDFARB, et al. 1995. Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. Blood 86: 2008-2013.
30. DE FRANCESCHI, L., O. SHALEV, A. PIGA, et al. 1999. Deferiprone therapy in homozygous human -thalassemia removes erythrocyte membrane free iron and reduces KCl co-transport activity. J. Lab. Clin. Med. 133: 64-69.
31. POOTRAKUL, P., W. BREUER, M. SAMETBAND, et al. 2004. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassaemia/HbE partients treated with an oral chelator. Blood 104: 1504-1510.
32. CIGHETTI, G., L. DUCA, L. BORTONE, et al. 2002. Oxidative status and malondialdehyde in β-thalassemia patients. Eur. J. Clin. Invest. 32: 55-60.
33. TESORIERE, L., D. D'ARPA, D. BUTERA, et al. 2001. Oral supplements of vitamin E improve measures of oxidative stress in plasma and reduce oxidative damage to LDL and erythrocytes in β-thalassemia intermedia patients. Free Radical Res. 34: 529-540.
34. RACHMILEWITZ, E.A., A. SHIFTER & I. KAHANE. 1979. Vitamin E deficiency in β-thalassemia major: changes in hematological and biochemical parameters after a therapeutic trial with α-tocopherol. Am. J. Clin. Nutr. 32: 1850-1858.
35. PACE, B.S., A. SHARTAVA, A. PACK-MABIEN, et al. 2003. Effects of N-acetylcysteine on dense cell formation in sickle cell disease. Am. J. Hematol. 73: 26-32.